Risankizumab-rzaa (Skyrizi) IV infusion — Induction for Crohn's disease and Ulcerative Colitis
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Covers medical necessity and prior-authorization requirements for risankizumab-rzaa (Skyrizi) intravenous infusion for adults with moderately to severely active Crohn's disease or ulcerative colitis; applies to Blue Cross Blue Shield North Carolina members and treating providers.
For Crohn's disease: removed required trial and failure of conventional therapy and replaced allowance for severely active disease with required demonstration of moderately to severely active disease by documented symptoms plus evidence of active inflammation OR significant extent/upper GI involvement OR corticosteroid-dependence/refractory to oral corticosteroids.
For ulcerative colitis: removed required trial and failure of conventional therapy and required demonstration of moderately to severely active disease by documented symptoms plus evidence of active inflammation or high-risk disease (with confirmatory criteria) OR corticosteroid-dependence/refractory to oral corticosteroids.
Added allowance for patients currently established on a biologic or systemic immunomodulator (not the requested agent) who have had positive clinical benefit from that agent.
Duration of induction approval adjusted to 90 days to allow scheduling all induction doses after authorization approval.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.